FDA要求诺和诺德修正误导性的口服Wegovy广告，并警告不安全的GLP-1复合药物。 FDA orders Novo Nordisk to fix misleading oral Wegovy ad and warns against unsafe compounded GLP-1 drugs.

美国食品和药物管理局已要求诺沃诺迪斯克纠正其口服Wegovy的电视广告, 引用了其优越减肥效益和误导性的情感吸引力的虚假宣称. The FDA has told Novo Nordisk to correct its TV ad for oral Wegovy, citing false claims of superior weight-loss benefits and misleading emotional appeals. 监管者还警告不要使用未经批准的复合GLP-1药物,这些药物没有经过林业发展局的审查,并且由于储存不当、标签欺诈和未核实成分而带来安全风险。 The regulator also warned against unapproved compounded GLP-1 drugs, which lack FDA review and pose safety risks due to improper storage, fraudulent labeling, and unverified ingredients. 该机构正在打击大规模销售的复合药物,敦促病人使用有执照的药店和BeSafeRx等可靠来源,同时强调只有经林业发展局批准的药物才能用于肥胖症治疗。 The agency is cracking down on mass-marketed compounded versions, urging patients to use licensed pharmacies and reliable sources like BeSafeRx, while emphasizing that only FDA-approved drugs should be used for obesity treatment.